![]() ![]() ![]() Results from a recent phase IIB clinical trial, CAPRISA 004, conducted in South Africa, showed for the first time evidence of microbicide efficacy against HIV-1 infection when used in a pericoital fashion. Microbicides, topically applied agents designed to prevent HIV-1 transmission ( 50), are a potential means of blocking the spread of infection through sexual intercourse. ![]() The need for additional preventative options against HIV infection, in the absence of a vaccine, stems from the inconsistent use of condoms, which results in sexual transmission continuing to fuel the HIV epidemic. Human immunodeficiency virus type 1 (HIV-1) is currently the cause of a worldwide epidemic. No cellular or tissue toxicity was detected in the presence of SQV, suggesting that this drug could be considered for development as a component of an effective microbicide, capable of blocking viral maturation and transmission of HIV-1 at mucosal surfaces. Moreover, SQV demonstrated inhibitory potency against trans infection of T cells by in vitro-derived dendritic cells and by primary dendritic cells that emigrate from penile and cervical tissue explants. ![]() SQV also inhibited production of infectious virus in cervical, penile, and colorectal explants cocultured with T cells. SQV inhibited replication of clade B and clade C isolates in a dose-dependent manner in all cellular models tested: PM-1 CD4 T cells, peripheral blood mononuclear cells (PBMCs), monocyte-derived macrophages (MDMs), and immature monocyte-derived dendritic cells (iMDDCs). We investigated the potential of saquinavir (SQV), a protease inhibitor (PI) used in highly active antiretroviral therapy (HAART), as a candidate microbicide. The maturation of newly formed human immunodeficiency virus type 1 (HIV-1) virions is a critical step for the establishment of productive infection. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |